Last reviewed · How we verify
JW Life Science — Portfolio Competitive Intelligence Brief
1 marketed
0 filed
2 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| SmofKabiven | SmofKabiven | marketed | Parenteral nutrition emulsion | Nutrition support / Critical care | ||
| CombiflexOmega | CombiflexOmega | phase 3 | ||||
| CombiflexOmega peri | CombiflexOmega peri | phase 3 |
Therapeutic area mix
- Nutrition support / Critical care · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Erasmus Medical Center · 1 shared drug class
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau · 1 shared drug class
- RWTH Aachen University · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for JW Life Science:
- JW Life Science pipeline updates — RSS
- JW Life Science pipeline updates — Atom
- JW Life Science pipeline updates — JSON
Cite this brief
Drug Landscape (2026). JW Life Science — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/jw-life-science. Accessed 2026-06-10.